

- 09.00 **Introductory Session**
Hardik Madlani, Senior VP, Jefferies Healthcare Investment Banking
Trends and activity in Business Development, M&A and Corporate Development
- 09:30 **What's new in IP?**
Andrew Wells, Partner HGF Ltd
An update on key issue and the impact on Business Development contracts including: the unitary patent, equivalence, impact of Brexit on IP strategy
- 10:30 **Asset Management: finding the best vehicle for commercialising your assets; deal strategies for partnering**
Neil Crabb, CEO, Frontier IP Group plc
Defining the partnering strategy
Licensing vs spin out vs SPV, what is really involved
Current approaches and use of options
How to calculate equity value
Role of corporate documentation
- 11.30 **Due diligence case study**
Martin Cadman, Due Diligence Director, Astra Zeneca
- 12:30 LUNCH
- What's new – an update on Legal aspects in BD Agreements**
Luke Kempton, Partner, Gowling WLG [UK] LLP
Updates on current legal issues in agreements
GDPR: what is needed to be included in the contract?
Changes required to accommodate Brexit
- 13:30
- 14.30 **What's new – an update on Regulatory issues**
Bob Clay, Board Director, TOPRA
Recent changes at the FDA and in Europe
EMA plan for UK companies and for EU companies,
MHRA plans for a hard Brexit
- 15:30 **Operational Aspects: the road map from MA to market**
Brian McEwan, Advisor, Cognital Ltd
Post grant of MA – how does the product reach the market?
Latest perspectives on supply chain management
Managing time frames and performance
- 16.30 **Transitional Service Agreements / Integration Programmes**
Stephen Kidner, Chief Scientific Affairs & Operations Officer, Alliance Pharma Ltd
What to cover to ensure continuity of supply
Operational topics and challenges
How to work to deliver success